What is the 13F Pro Quality Score for XRAY?

13F Pro ranks DENTSPLY SIRONA Inc. (XRAY) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View XRAY's current score at https://13fpro.ai/research/XRAY (free sign-up required for the full ranking).

Where does 13F Pro source XRAY data?

All DENTSPLY SIRONA Inc. fundamentals and ownership data come directly from SEC EDGAR. DENTSPLY SIRONA Inc. files with the SEC under CIK 818479. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is XRAY in?

DENTSPLY SIRONA Inc. (XRAY) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is XRAY research updated on 13F Pro?

XRAY's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

DENTSPLY SIRONA Inc.(XRAY)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 818479 XRAY stock profile & AI dashboard →

13F Pro Quality Score

37.0/100

Rank #2,076 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

21.0/100

Profitability

24.4/100

Balance Sheet

19.1/100

Earnings Quality

30.0/100

Free Cash Flow

36.5/100

Institutional Flow

82.2/100

Revenue Scale

72.8/100

Dilution Risk

60.1/100

XRAY Stock Analysis & AI Quality Score

AI stock analysis and institutional research for DENTSPLY SIRONA Inc. (XRAY), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores XRAY at 37.0/100 on a 32-signal composite quality model, placing it at rank #2,076 of 2,879 stocks — the bottom half of the AI-ranked universe. XRAY scores in the top quartile across institutional flow (82.2). Areas of concern include balance sheet strength (19.1) and revenue growth (21.0), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q1 2026), DENTSPLY SIRONA Inc. reports quarterly revenue of $880.0M, net income of $-10.0M, free cash flow of $-12.0M. Top institutional holders of XRAY by reported 13-F value include BlackRock,, First Eagle Investment Management,, FULLER & THALER ASSET MANAGEMENT,, based on the most recent SEC filings. XRAY trades on the Nasdaq exchange and files with the SEC under CIK 818479. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate XRAY daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for DENTSPLY SIRONA Inc. directly from SEC EDGAR. DENTSPLY SIRONA Inc.'s 13F Pro composite quality score has ranged between 8 and 57 since 2021, currently 37.0 — a declining long-term trajectory across 56 quarterly and live scoring snapshots.

Revenue

Q1 2026

$880.0M

Net Income

Q1 2026

$-10.0M

Free Cash Flow

Q1 2026

$-12.0M

D/E Ratio

Q1 2026

1.70

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-4.3% YoY

$3.79BFY 2024

FY19 $4.02BFY20 $3.34BFY23 $3.96BFY24 $3.79B

Net Income

-589.4% YoY

$-910.0MFY 2024

FY19 $256.0MFY20 $-73.0MFY23 $-132.0MFY24 $-910.0M

Operating Income

-934.1% YoY

$-879.0MFY 2024

FY19 $361.0MFY20 $-3.0MFY23 $-85.0MFY24 $-879.0M

EPS (Diluted)

-622.6% YoY

$-4.48FY 2024

FY19 $1.14FY20 $-0.33FY23 $-0.62FY24 $-4.48

Total Assets

-21.9% YoY

$5.75BFY 2024

FY19 $8.60BFY20 $9.34BFY23 $7.37BFY24 $5.75B

Total Debt

+5.1% YoY

$2.42BFY 2024

FY19 $1.44BFY20 $2.88BFY23 $2.31BFY24 $2.42B

Op. Cash Flow

+22.3% YoY

$461.0MFY 2024

FY19 $639.0MFY20 $649.0MFY23 $377.0MFY24 $461.0M

Metric	FY 2024	FY 2023	FY 2020	FY 2019	FY 2018	FY 2017
Revenue	$3.79B -4.3%	$3.96B +18.7%	$3.34B -17.0%	$4.02B +0.9%	$3.99B -0.2%	$3.99B
Net Income	$-910.0M -589.4%	$-132.0M -80.8%	$-73.0M -128.5%	$256.0M +125.3%	$-1.01B +34.8%	$-1.55B
Operating Income	$-879.0M -934.1%	$-85.0M -2733.3%	$-3.0M -100.8%	$361.0M +137.7%	$-958.0M +38.7%	$-1.56B
EPS (Diluted)	$-4.48 -622.6%	$-0.62 -87.9%	$-0.33 -128.9%	$1.14 +125.3%	$-4.51 +33.3%	$-6.76
Total Assets	$5.75B -21.9%	$7.37B -21.1%	$9.34B +8.6%	$8.60B -1.0%	$8.69B -16.3%	$10.37B
Total Debt	$2.42B +5.1%	$2.31B -19.8%	$2.88B +99.9%	$1.44B -14.4%	$1.68B +1.1%	$1.67B
Operating Cash Flow	$461.0M +22.3%	$377.0M -41.9%	$649.0M +1.6%	$639.0M +27.8%	$500.0M -16.9%	$601.9M

AI Insight: XRAY Financial Trends

DENTSPLY SIRONA's equity has collapsed from $3,064M to $1,318M in seven quarters as persistent operating losses and rising debt erode the balance sheet.

• Revenue has declined from $984M in Q2 2024 to $880M in Q1 2026, a roughly 11% contraction over seven quarters.

• Operating income swung from $50M in Q2 2024 to -$35M in Q1 2026, with six of the last eight quarters reporting operating losses.

• Total debt rose from $2,099M in Q2 2024 to $2,817M in Q4 2025, before a modest dip to $2,236M in Q1 2026.

• Operating cash flow has been volatile, ranging from $7M in Q1 2025 to $208M in Q2 2024, with no stable recovery trend.

⚠ Equity deteriorated from $2,491M in Q3 2024 to $1,318M in Q1 2026 — solvency risk increases if losses persist.

⚠ Debt jumped to $2,817M in Q4 2025 before falling to $2,236M in Q1 2026 — monitor whether debt reduction is sustained.

⚠ Operating income improved sequentially from -$218M in Q3 2025 to -$35M in Q1 2026 — watch for a return to profitability.

AI Insight: XRAY Ratio Trends

DENTSPLY SIRONA remains deeply unprofitable across all return metrics, with D/E surging to 2.10x in Q4 2025 before easing slightly — structural losses show no clear recovery path.

• Operating margin has been negative in 6 of the last 7 reported quarters, ranging from -56.2% in Q4 2024 to -4.0% in Q1 2026.

• ROIC deteriorated from 3.9% in Q2 2024 to -46.6% in Q4 2024, recovering only partially to -3.9% in Q1 2026.

• Debt-to-equity ratio nearly tripled from 0.69 in Q2 2024 to 2.10 in Q4 2025, reflecting significant balance sheet deterioration.

• Q1 2026 shows marginal improvement — OpMargin at -4.0% and NPM at -1.1% — versus much deeper losses in prior quarters.

⚠ D/E remains elevated at 1.70x on a TTM basis; further leverage increases could pressure refinancing and liquidity.

⚠ The single profitable quarter (Q1 2025, NPM 2.3%) proved unsustainable — watch whether Q1 2026's improvement persists.

⚠ TTM ROE of -47.6% and ROIC of -14.6% suggest ongoing goodwill/asset impairments may continue distorting reported results.

Get alerted when XRAY's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for DENTSPLY SIRONA Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of XRAY

BlackRock, Inc.
$223.3M19,251,869 sh
First Eagle Investment Management, LLC
$175.5M15,127,933 sh
FULLER & THALER ASSET MANAGEMENT, INC.
$148.4M12,792,518 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$122.2M10,530,746 sh
Southpoint Capital Advisors LP
$116.0M10,000,000 sh
VANGUARD CAPITAL MANAGEMENT LLC
$104.4M8,999,557 sh
COOKE & BIELER LP
$90.5M7,801,187 sh
STATE STREET CORP
$84.0M7,244,837 sh
LAZARD ASSET MANAGEMENT LLC
$77.9M6,715,763 sh
ARIEL INVESTMENTS, LLC
$74.1M6,386,815 sh

Fund	Value	Shares
BlackRock, Inc.	$223.3M	19,251,869
First Eagle Investment Management, LLC	$175.5M	15,127,933
FULLER & THALER ASSET MANAGEMENT, INC.	$148.4M	12,792,518
VANGUARD PORTFOLIO MANAGEMENT LLC	$122.2M	10,530,746
Southpoint Capital Advisors LP	$116.0M	10,000,000
VANGUARD CAPITAL MANAGEMENT LLC	$104.4M	8,999,557
COOKE & BIELER LP	$90.5M	7,801,187
STATE STREET CORP	$84.0M	7,244,837
LAZARD ASSET MANAGEMENT LLC	$77.9M	6,715,763
ARIEL INVESTMENTS, LLC	$74.1M	6,386,815

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put XRAY on your watchlist

Track score changes the day DENTSPLY SIRONA Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is XRAY a good stock to buy?

13F Pro's AI-powered analysis of DENTSPLY SIRONA Inc. (XRAY) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for XRAY are available on the XRAY stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own XRAY?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling XRAY. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of DENTSPLY SIRONA Inc.'s investment landscape.